Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 145
Filter
1.
Calcif Tissue Int ; 72(4): 519-27, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12574877

ABSTRACT

Zoledronic acid (ZOL) is a highly potent heterocyclic bisphosphonate which has been shown to inhibit bone resorption in short-term experiments in young growing animals. In this investigation we have evaluated the effects of a 1-year administration to mature, ovariectomized (OVX) rats as a model for postmenopausal osteoporosis in order to elucidate (1) the temporal changes in urinary biochemical markers of bone turnover and femoral bone mineral density (BMD), (2) to measure changes of static and dynamic histomorphometric parameters and mechanical strength, and (3) to assess the preventive effects of chronic treatment with ZOL on these parameters. In urine, deoxypyridinoline increased after OVX and was significantly reduced by ZOL administration, indicative of a reduced bone collagen turnover. These changes were accompanied by alterations of tibial cancellous bone: trabecular bone volume and parameters of bone architecture were significantly augmented by ZOL and bone formation rates fell as a consequence of suppressed bone turnover, but were still measurable. No signs of "frozen bone" or osteomalacia could be detected. BMD of the whole femurs rose in sham-operated control animals (SHAM) during the entire experimental period, whereas in OVX animals, BMD plateaued after 32 weeks at a lower level. ZOL at a low dose (0.3 mg/kg/week s.c.) did not alter whole femur BMD, but at higher doses (1.5 and 7.5 mg/kg/week s.c.) BMD increased to the level of the SHAM group. A distinct pattern was noted for the distal quarter of the femur, a region rich in cancellous bone: BMD initially increased in all treatment groups except the OVX group, and at a later stage fell again at a comparable rate irrespective of treatment. Mechanical stability, as assessed by a 3-point bending test, was significantly increased by all doses of ZOL and exceeded OVX and sham-operated controls. The effects on mechanical properties were observed at a low dose which did not measurably increase femoral BMD after 1-year treatment. Multiregression analysis revealed a significant positive correlation between maximum load and BMD, and a significant negative correlation of maximum load with labeled perimeter, a marker of bone formation and turnover. No significant correlation was found with urinary deoxypyridinoline, a marker of bone resorption. The data show that mechanical testing detects improvements of functional bone quality following low dose bisphosphonate treatment which are not identified by standard DXA measurements of BMD.


Subject(s)
Bone Density/drug effects , Bone and Bones/drug effects , Diphosphonates/pharmacology , Imidazoles/pharmacology , Osteoporosis, Postmenopausal/drug therapy , Animals , Bone Density/physiology , Bone Resorption/drug therapy , Bone Resorption/metabolism , Bone Resorption/physiopathology , Bone and Bones/metabolism , Bone and Bones/physiopathology , Diphosphonates/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Femur/drug effects , Femur/metabolism , Femur/physiopathology , Humans , Imidazoles/therapeutic use , Osteoporosis, Postmenopausal/metabolism , Osteoporosis, Postmenopausal/physiopathology , Ovariectomy , Rats , Rats, Sprague-Dawley , Weight-Bearing/physiology , Zoledronic Acid
2.
Rev. Soc. Esp. Dolor ; 9(8): 485-501, dic. 2002. ilus, graf
Article in Es | IBECS | ID: ibc-18902

ABSTRACT

En este artículo se describe el primer modelo conocido de dolor por cáncer de huesos en la rata. Ratas SpragueDawley recibieron inyecciones intratibiales de células M R M T-1 singénicas de carcinoma de glándula mamaria de rata y exhibieron conductas indicativas de dolor, como: alodinia mecánica, diferencia en el peso apoyado en las patas traseras e hiperalgesia mecánica. La aparición del tumor óseo y el daño estructural del hueso se vigilaron mediante análisis radiológico, medidas cuantitativas del contenido mineral e histología. Las inyecciones intratibiales de 3 x 103 ó 3 x 104 células M R M T-1 singénicas produjeron un tumor que se propagó rápidamente dentro de la tibia, causando una intensa remodelación del hueso. Las radiografías mostraron importantes daños en el hueso cortical y las trabéculas entre 10 y 14 días después de la inoculación de 3 x 103 células MRMT-1 y, al cabo de 20 días, los daños amenazaban la integridad de la tibia. Mientras que el contenido mineral y la densidad mineral disminuyeron significativamente en hueso afectado por el cáncer, el número de osteoclastos en el hueso compacto peritumoral no experimentó cambios. Sin embargo, la tinción con fosfatasa ácida resistente al tartarato puso de manifiesto la existencia de un gran número de células policariotas parecidas a los osteoclastos presentes dentro del tumor. No se observó crecimiento tumoral después de la inyección de células MRMT-1 destruidas con calor. Las inyecciones intratibiales de 3 x 103 ó 3 x 104 de células MRMT-1, células destruidas con calor o excipiente no p ro d u j e ron cambios en el peso corporal ni en la temperatura interna en los 19-20 días siguientes. La actividad general en los animales que recibieron una inyección de células MRMT-1 vivas o destruidas con calor fue mayor que en los animales de control, pero la actividad del grupo tratado con células MRMT-1 disminuyó al avanzar la enfermedad. En las ratas que recibieron inyecciones intratibiales de células MRMT-1 se produjo la aparición gradual de alodinia mécanica e hiperalgesia mecánica/disminución del peso apoyado en el miembro afectado, a partir de 12-14 ó 1012 días después de la inyección de 3 x 103 ó 3 x 104 células, respectivamente. Estos síntomas no se observaron en las ratas que recibieron células destruidas con calor o excipiente. Los datos sobre la conducta de los animales sugieren un intervalo razonable para la evaluación de los agentes antinociceptivos entre el día 14 y el día 20 después de la inoculación de las células cancerosas en este modelo. El tratamiento agudo con morfina (1-3 mg.kg- 1, por vía subcutánea (s.c.)) consiguió una disminución proporcional a la dosis de la frecuencia de respuesta de retirada de la pata trasera frente a estimulación con filamentos de von Fre y 17 ó 19 días después de la inyección de 3 x 103 células M R M T-1. Se observó también una reducción significativa de la diferencia en el peso apoyado en las patas traseras. El tratamiento agudo con celebrex (10-30 mg.kg- 1 s.c.) no influyó en la alodinia mecánica ni en el diferente peso apoyado en las patas traseras de las ratas 20 días después del tratamiento con 3 x 103 células MRMT- 1 .Aunque la fisiopatología del dolor oncológico no se conoce bien, el aumento significativo de la tinción con proteína acídica fibrilar glial (GFAP) en los correspondientes segmentos de la médula espinal ipsilateral sugiere una posible participación de los astrocitos. En resumen, la inducción de cáncer de huesos en la rata con la línea de células MRMT-1 singénicas de cáncer mamario constituye un modelo preclínico válido del dolor asociado a metástasis óseas. Al progresar el tumor en la cavidad de la médula ósea parece una marcada hiperalgesia mecánica y alodinia, aunque el estado general del animal sigue siendo satisfactorio. El tratamiento agudo con morfina tiene cierto efecto analgésico en el peso apoyado en las patas traseras, pero celebrex, un inhibidor selectivo de COX-2, no influye en los cambios de conducta relacionados con el dolor en este modelo. (AU)


Subject(s)
Animals , Rats , Pain/chemically induced , Bone Neoplasms/chemically induced , Pain/physiopathology , Pain/drug therapy , Cancerous Symptoms , Nociceptors , Hyperalgesia/chemically induced , Bone Density , Weight Loss , Morphine/pharmacology , Bone Neoplasms/physiopathology
3.
Pain ; 96(1-2): 129-40, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11932069

ABSTRACT

This study describes the first known model of bone cancer pain in the rat. Sprague-Dawley rats receiving intra-tibial injections of syngeneic MRMT-1 rat mammary gland carcinoma cells developed behavioural signs indicative of pain, including: mechanical allodynia, difference of weight bearing between hind paws and mechanical hyperalgesia. The development of the bone tumour and structural damage to the bone was monitored by radiological analysis, quantitative measurement of mineral content and histology. Intra-tibial injections of 3 x 10(3) or 3 x 10(4) syngeneic MRMT-1 cells produced a rapidly expanding tumour within the boundaries of the tibia, causing severe remodelling of the bone. Radiographs showed extensive damage to the cortical bone and the trabeculae by day 10-14 after inoculation of 3 x 10(3) MRMT-1 cells, and by day 20, the damage was threatening the integrity of the tibial bone. While both mineral content and mineral density decreased significantly in the cancerous bone, osteoclast numbers in the peritumoural compact bone remained unchanged. However, tartarate-resistant acid phosphatase staining revealed a large number of polykariotic cells, resembling those of osteoclasts within the tumour. No tumour growth was observed after the injection of heat-killed MRMT-1 cells. Intra-tibial injections of 3 x 10(3) or 3 x 10(4) MRMT-1 cells, heat-killed cells or vehicle did not show changes in body weight and core temperature over 19-20 days. The general activity of animals after injection with live or heat-killed MRMT-1 cells was higher than that of the control group, however, the activity of the MRMT-1 treated group declined during the progress of the disease. Rats receiving intra-tibial injections of MRMT-1 cells displayed the gradual development of mechanical allodynia and mechanical hyperalgesia/reduced weight bearing on the affected limb, beginning on day 12-14 or 10-12 following injection of 3 x 10(3) or 3 x 10(4) cells, respectively. These symptoms were not observed in rats receiving heat-killed cells or vehicle. Behavioural data suggest a reasonable time window for evaluation of anti-nociceptive agents between day 14 and 20 after cancer cell inoculation in this model. Acute treatment with morphine (1-3mg/kg, subcutanously (s.c.)) produced a dose-dependent reduction in the response frequency of hind paw withdrawal to von Frey filament stimulation 17 or 19 days following intra-tibial injections of 3 x 10(3) MRMT-1 cells. A significant reduction in the difference in hind limb weight bearing was also observed. Acute treatment with celebrex (10-30 mg/kg, s.c.) did not affect mechanical allodynia or difference in weight bearing in rats 20 days following treatment with 3 x 10(3) MRMT-1 cells. Although the pathophysiology of cancer pain is largely unknown, significant enhancement of glial fibrillary acidic protein (GFAP) staining in the corresponding segments of the ipsilateral spinal cord highlights the possible involvement of astrocytes. In summary, the induction of bone cancer in the rat by the syngeneic MRMT-1 mammary tumour cell line provides a valid pre-clinical model for pain associated with bone metastases. Significant mechanical hyperalgesia and allodynia develops in association with the progression of the tumour in the bone marrow cavity, while the general condition of the animal remains satisfactory. While acute treatment with morphine has some analgesic effect on hind limb sparing the selective COX-2 inhibitor, celebrex, has no influence on the pain-related behavioural changes in this model.


Subject(s)
Bone Neoplasms/complications , Disease Models, Animal , Pain/physiopathology , Rats, Sprague-Dawley , Analgesics, Opioid/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Behavior, Animal , Body Temperature , Body Weight , Bone Density , Bone Morphogenetic Proteins/analysis , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/pathology , Celecoxib , Female , Glial Fibrillary Acidic Protein/analysis , Mammary Neoplasms, Experimental , Morphine/administration & dosage , Neoplasm Transplantation , Osteoclasts/pathology , Pain/drug therapy , Pain/pathology , Physical Stimulation , Pyrazoles , Radiography , Rats , Spinal Cord/chemistry , Sulfonamides/pharmacology , Tibia/chemistry , Tibia/diagnostic imaging , Tibia/pathology , Weight-Bearing
4.
Curr Med Chem Anticancer Agents ; 1(3): 313-29, 2001 Nov.
Article in English | MEDLINE | ID: mdl-12678761

ABSTRACT

A variety of cancers are associated with bone. Primary tumors can arise in bone, common cancers, such as those of breast and prostate origin, metastasize to bone, and multiple myeloma neoplastic disease affects bone profoundly. The cellular and molecular mechanisms underlying these pathological processes are increasingly being understood. The interaction of tumor cells with bone cells, osteoblasts and osteoclasts, and with the bone local environment is a new promising direction in research, which should help to develop new therapies. In this article we will relate the newest developments in the molecular research to the pathology of the tumor bone disease. Potential new targets for drugs, aimed specifically at tumor bone diseases, will be highlighted. Furthermore, we will describe the existing compounds that are either used in treatment or have a potential as therapeutic agents, such as bisphosphonates, Src inhibitors, and selective estrogen receptor modulators.


Subject(s)
Bone Neoplasms/drug therapy , Bone Neoplasms/genetics , Animals , Bone Neoplasms/pathology , Bone Neoplasms/secondary , Bone and Bones/cytology , Bone and Bones/physiology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Humans , Neoplasm Metastasis/pathology , Receptors, Cell Surface/drug effects , Receptors, Cell Surface/physiology
5.
Eur Cell Mater ; 1: 18-26, 2001 Jan 10.
Article in English | MEDLINE | ID: mdl-14562267

ABSTRACT

The effect of long-term treatment with the bisphosphonate zoledronate on vertebral bone architecture was investigated in estrogen-deficient mature rats. 4-month-old rats were ovariectomized and development of cancellous osteopenia was assessed after 1 year. The change of bone architectural parameters was determined with a microtomographic instrument of high resolution. After 1 year of estrogen-deficiency, animals lost 55% of vertebral trabecular bone in comparison to sham operated control animals. Trabecular number (Tb.N) and trabecular thickness (Tb.Th) were significantly reduced in ovariectomized animals, whereas trabecular separation (Tb.Sp), bone surface to volume fraction (BS/BV) and trabecular bone pattern factor (TBPf) were significantly increased, indicating a loss of architectural integrity throughout the vertebral body. 3 groups of animals were treated subcutaneously with zoledronate for 1 year with 0.3, 1.5 and 7.5 microgram/kg/week to inhibit osteoclastic bone degradation. Administration started immediately after ovariectomy and treatment dose-dependently prevented the architectural bone deterioration and completely suppressed the effects of estrogen deficiency at the higher doses. The results show that microtomographic determination of static morphometric parameters can be used to quantitate the effects of drugs on vertebral bone architecture in small laboratory animals and that zoledronate is highly effective in this rat model.

6.
Can Fam Physician ; 45: 1509-15, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10386215

ABSTRACT

OBJECTIVE: To explore participants' overall perception of the value of the Peer Consultation Reflection Exercise (PCRE); of barriers and facilitators to participation and learning during a PCRE; and of the transferability of the experience to participants' own settings. DESIGN: This study used the qualitative techniques of key informant interviews and a focus group. SETTING: Focus group and key informant interviews at the 1996 Annual Meeting of the College of Family Physicians of Canada's Section of Teachers. PARTICIPANTS: Family medicine teachers attending a PCRE. METHOD: Five key informant interviews and one focus group composed of five participants were conducted to explore participants' experience of participating and learning during a PCRE. MAIN FINDINGS: Participants viewed the PCRE as a valuable opportunity to interact and learn from colleagues a were especially impressed with the opportunity to listen. Confidentiality and the important role of the facilitator were identified as key components. The greatest perceived barrier was the formal structure of the PCRE. CONCLUSIONS: The PCRE is an innovative strategy for personal and professional development. It could be used in other settings.


Subject(s)
Education, Medical, Continuing , Family Practice/education , Peer Group , Adult , Communication Barriers , Humans , Interprofessional Relations , Professional Competence
7.
Bone ; 24(5): 437-49, 1999 May.
Article in English | MEDLINE | ID: mdl-10321903

ABSTRACT

The tyrosine kinase Src has been implicated in the process of osteoclast-mediated bone resorption. Here, we describe a novel class of Src inhibitors, substituted 5,7-diphenyl-pyrrolo[2,3-d]pyrimidines, and characterize one of them, CGP77675, in vitro and in models of bone resorption in vivo. In vitro, CGP77675 inhibited phosphorylation of peptide substrates and autophosphorylation of purified Src (concentration producing half-maximal inhibition [IC50] values 5-20 and 40 nmol/L, respectively). The compound was selective toward other protein kinases: the Src IC50 value was lower than those for Cdc2 (>500-fold), epidermal growth factor (EGF) receptor (7.5-fold), and vascular endothelial growth factor receptor (>50-fold), and for v-Abl (15-fold) and focal adhesion kinase (Fak) (>25-fold). The Src kinase family members Lck and Yes were inhibited with IC50 values 20-fold higher than or equal to Src. To measure the inhibition of cellular Src activity, we identified the major tyrosine-phosphorylated proteins in an Src-overexpressing cell line IC8.1 as Src, Fak, and paxillin. CGP77675 potently inhibited tyrosine phosphorylation of the Src substrates Fak and paxillin, but had much less effect on Src (IC50 values 0.3, 0.5, and 5.7 micromol/L). The phosphorylation of Src in IC8.1 cells reflected phosphorylation of the negative regulatory tyrosine 527 (Y527); thus, the inhibitor was selective against the Y527 C-terminal Src kinase Csk. In osteoblastic MC3T3-E1 cells, CGP77675 inhibited signaling induced by PDGF at the receptor level, but not signaling by EGF, basic fibroblast growth factor, insulin-like growth factor-1, and phorbol 12-myristate 13-acetate. The effect of CGP77675 on bone resorption was evaluated in vitro and in vivo. The parathyroid hormone-induced bone resorption in rat fetal long bone cultures was inhibited with an IC50 of 0.8 micromol/L. CGP77675 dose-dependently reduced the hypercalcemia induced in mice by interleukin-1beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. Thus, specific Src family kinase inhibitors may be useful for the treatment of diseases associated with elevated bone loss.


Subject(s)
Bone Resorption/prevention & control , Enzyme Inhibitors/pharmacology , Osteoblasts/drug effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyrimidines/pharmacology , Pyrroles/pharmacology , 3T3 Cells , Animals , Bone Diseases, Metabolic/drug therapy , Bone Resorption/drug therapy , CSK Tyrosine-Protein Kinase , Cell Adhesion Molecules/metabolism , Cell Survival/drug effects , Cytoskeletal Proteins/metabolism , Disease Models, Animal , Female , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Male , Mice , Oncogene Protein pp60(v-src)/metabolism , Osteoblasts/cytology , Osteoblasts/enzymology , Ovariectomy , Paxillin , Phosphoproteins/metabolism , Phosphorylation/drug effects , Pregnancy , Protein-Tyrosine Kinases/metabolism , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Rats , Rats, Sprague-Dawley , src-Family Kinases
9.
J Rheumatol ; 21(11): 1992-7, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7869300

ABSTRACT

OBJECTIVE: CGP 47969A is a novel and potent inhibitor of cytokine biosynthesis in human and murine monocytic cells. The effect of CGP 47969A on collagen induced arthritis (CIA) in DBA/1 mice was investigated and compared to that of prednisolone. METHODS: CIA was induced by intradermal injection of type II collagen in CFA at Day 0. CGP 47969A was applied orally, 5 times/week, starting at Day 15 after immunization. Arthritic signs were recorded 3 times/week for clinical scoring and radiographic analysis was performed at the end of the experiment at Day 60. Serum amyloid P (SAP) and anticollagen antibody titers were determined by ELISA at Day 60. RESULTS: CGP 47969A dose dependently reduced the incidence of arthritis from 93% in the positive control group to 60, 40, 30 and 10% at doses of 1, 5, 25 and 60 mg/kg/day, respectively. At a dose of 120 mg/kg, CGP 47969A totally prevented the occurrence of arthritis (ED50 between 1 and 5 mg/kg). Prednisolone at 3 and 30 mg/kg reduced the arthritis incidence to 70 and 30%, respectively. CGP 47969A dose dependently inhibited the joint destruction, as measured by radiographic scoring and its potency was comparable to that of prednisolone. The elevated serum levels of the positive acute phase protein SAP in arthritic animals were completely normalized by CGP 47969A at a dose of 60 mg/kg, however, neither CGP 47969A nor prednisolone influenced the plasma levels of anticollagen antibodies (IgG). CONCLUSION: Our results demonstrate that CGP 47969A is highly effective in CIA with a potency comparable to that of prednisolone. These promising results justify the expectation that this novel antiarthritic compound now under development might also be effective in the treatment of rheumatoid arthritis in man.


Subject(s)
Arthritis/drug therapy , Piperazines/therapeutic use , Acute Disease , Animals , Arthritis/chemically induced , Arthritis/diagnostic imaging , Body Weight/drug effects , Collagen/immunology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Immunization , Immunoglobulin G/blood , Male , Mice , Mice, Inbred DBA , Prednisolone/therapeutic use , Radiography , Serum Amyloid P-Component/analysis
10.
Blood ; 83(3): 636-40, 1994 Feb 01.
Article in English | MEDLINE | ID: mdl-7507729

ABSTRACT

Peripheral blood progenitor cells (PBPCs) are increasingly used for autografting after high-dose chemotherapy. One advantage of PBPCs over the use of autologous bone marrow would be a reduced risk of tumor-cell contamination. However, the actual level of tumor cells contaminating PBPC harvests is poorly investigated. It is currently not known whether mobilization of PBPCs might also result in mobilization of tumor cells. We evaluated 358 peripheral blood samples from 46 patients with stage IV or high-risk stage II/III breast cancer, small cell (SCLC) or non-small cell (NSCLC) lung cancer, as well as other advanced malignancies for the detection of epithelial tumor cells. Monoclonal antibodies against acidic and basic cytokeratin components and epithelial antigens (HEA) were used in an alkaline phosphatase-anti-alkaline phosphatase assay with a sensitivity of 1 tumor cell within 4 x 10(5) total cells. Before initiation of PBPC mobilization, circulating tumor cells were detected in 2/7 (29%) patients with stage IV breast cancer and in 2/10 (20%) patients with extensive-disease SCLC, respectively. In these patients, an even higher number of circulating tumor cells was detected after chemotherapy with VP16, ifosfamide, and cisplatin (VIP) followed by granulocyte colony-stimulating factor (G-CSF). This approach has previously been shown to be highly effective in mobilizing PBPCs. In the 42 patients without circulating tumor cells during steady state, tumor cells were mobilized in 9/42 (21%) patients after VIP+G-CSF induced recruitment of PBPCs. The overall incidence of tumor cells varied between 4 and 5,600 per 1.6 x 10(6) mononuclear cells analyzed. All stage IV breast cancer patients and 50% of SCLC patients were found to concomitantly mobilize tumor cells and PBPCs. Kinetic analyses showed two patterns of tumor cell recruitment depending on the presence or absence of bone marrow disease: (1) early after chemotherapy (between days 1 and 7) in patients without marrow infiltration, and (2) between days 9 and 16 in patients with marrow infiltration, ie, within the optimal time period for the collection of PBPCs. We show that there is a high proportion of patients with circulating tumor cells under steady-state conditions, and in addition a substantial risk of concomitant tumor cell recruitment upon mobilization of PBPCs, particularly in stage IV breast cancer patients with bone marrow infiltration. The biologic and clinical significance of this finding is unknown at present.


Subject(s)
Bone Marrow/pathology , Hematopoietic Stem Cells/pathology , Neoplasms/pathology , Neoplastic Cells, Circulating , Adult , Breast Neoplasms/pathology , Carcinoma, Small Cell/pathology , Cell Movement/drug effects , Female , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/drug effects , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasms/blood
11.
Clin Exp Rheumatol ; 11(5): 515-22, 1993.
Article in English | MEDLINE | ID: mdl-8275587

ABSTRACT

Interleukin-1 (IL-1) has been implicated in the development and progression of a variety of acute and chronic inflammatory diseases. Due to its pro-inflammatory and tissue-degrading activities, IL-1 is regarded as a major mediator of chronic inflammatory joint diseases, including rheumatoid arthritis in man, adjuvant arthritis in rats and collagen-induced arthritis in mice. However, conclusive experimental evidence for the crucial role of IL-1 in the development of joint destruction has not been presented as yet. In the present study, we investigated the effect of a neutralizing monoclonal mouse antibody against mouse IL-1 beta (IgG1 isotype) on the development and progression of collagen-induced arthritis in DBA/1 mice. The antibody was injected intraperitoneally 3 times a week, either from day 3 or from day 21 after primary immunization, to day 60. In the positive control group an arthritis incidence of 80% was observed after 60 days. The injection of a control antibody of the same isotype did not influence the incidence of arthritis, whereas injection of anti-IL-1 beta from day 21 reduced the arthritis incidence to about 30%. Injection of anti-IL-1 beta starting at day 3 totally prevented both the development of arthritis and the associated increase of the acute phase protein serum amyloid P (SAP). Anti-collagen antibody titers, which increased significantly after immunization, were not influenced by the injection of anti-IL-1 beta antibodies, in spite of the suppressive effect on arthritis development.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antibodies, Monoclonal/pharmacology , Arthritis, Rheumatoid/prevention & control , Collagen/immunology , Interleukin-1/antagonists & inhibitors , Acute-Phase Reaction/etiology , Acute-Phase Reaction/prevention & control , Animals , Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/immunology , Autoantibodies/biosynthesis , Disease Models, Animal , Interleukin-1/immunology , Male , Mice , Mice, Inbred DBA , Neutralization Tests , Serum Amyloid P-Component/metabolism , T-Lymphocytes/immunology
14.
Lancet ; 336(8727): 1385, 1990 Dec 01.
Article in English | MEDLINE | ID: mdl-1978196
15.
Lancet ; 336(8729): 1512, 1990 Dec 15.
Article in English | MEDLINE | ID: mdl-1979120
16.
Clin Nurse Spec ; 4(1): 3-9, 1990.
Article in English | MEDLINE | ID: mdl-2317719

ABSTRACT

The paper presents a family systems nursing approach to premenstrual syndrome. The interaction between premenstrual syndrome and family dynamics becomes the focus for the clinical nurse specialist and her team. A case example illustrates the use of the interview guidelines of hypothesizing, circularity and neutrality and various systemic-strategic interventions. through this process the couple's maladaptive patterns of interaction are interrupted. Symptom prescription, symptom sharing, symptom escalation, and positive connotation are among the creative interventions used to release premenstrual syndrome from its triangulated position in the marriage.


Subject(s)
Family Therapy , Nurse Clinicians/methods , Premenstrual Syndrome/nursing , Adaptation, Psychological , Adult , Female , Humans , Interview, Psychological , Male , Marriage/psychology , Premenstrual Syndrome/psychology , Premenstrual Syndrome/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...